Phase I/II trial of RAD001 Plus Docetaxel in Patients with Metastatic or Recurrent Non-Small Cell Lung Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 23 Jul 2015
At a glance
- Drugs Docetaxel (Primary) ; Everolimus (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Jun 2012 Planned end date changed from 1 May 2012 to 1 May 2013 as reported by ClinicalTrials.gov.
- 25 May 2012 Actual patient number changed from 53 to 28 as reported by ClinicalTrials.gov.